Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06647263 in advanced solid tumors
NCT02078752Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Apr 2014
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF-06647263 in solid tumor and triple-negative breast cancer (TNBC) (2 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Dose Limiting Toxicities and Objective Response Rate up to 24 months. Started Apr 2014; status: terminated.
02
Drugs
PF-06647263
03
Conditions
solid tumortriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02078752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02078752.